INDIUM IN 111 IBRITUMOMAB TIUXETAN

Summary

Indium In 111 Ibritumomab Tiuxetan (CHEMBL2108610) is a phase-3 clinical-stage antibody; indicated across 14 conditions including diffuse large b-cell lymphoma and follicular lymphoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 14 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108610
Name	INDIUM IN 111 IBRITUMOMAB TIUXETAN
Type	Antibody
Max phase	3

Also known as: 111indium-zevalin, Zevalin indium in-111, INDIUM IN 111 IBRITUMOMAB TIUXETAN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

14 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diffuse large B-cell lymphoma	3	MONDO:0018905	EFO:0000403
follicular lymphoma	3	MONDO:0018906	MONDO:0018906
leukemia	2	MONDO:0005059	EFO:0000565
lymphoma	2	MONDO:0005062	EFO:0000574
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
graft versus host disease	2	MONDO:0013730	MONDO:0013730
B-cell chronic lymphocytic leukemia	1	MONDO:0004948	EFO:0000095
Hodgkins lymphoma	1	MONDO:0004952	EFO:0000183
MALT lymphoma	1	MONDO:0007650	EFO:0000191
plasma cell neoplasm	1	MONDO:0004959	EFO:0000200
Burkitt lymphoma	1	MONDO:0007243	EFO:0000309
Waldenstrom macroglobulinemia	1	MONDO:0100280	EFO:0009441

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE2	4
PHASE1/PHASE2	3
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00005592	PHASE2	COMPLETED	Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma
NCT00012298	PHASE1/PHASE2	TERMINATED	Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma
NCT00058422	PHASE2	COMPLETED	Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
NCT00064246	PHASE1/PHASE2	COMPLETED	Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder
NCT00088881	PHASE2	TERMINATED	Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin’s Lymphoma
NCT00089284	PHASE1/PHASE2	TERMINATED	Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
NCT00577278	PHASE2	COMPLETED	A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
NCT00036855	PHASE1	TERMINATED	Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).